Indigenous Plants Against Cytomegalovirus, Cytomegalovirus B1, and Epstein-Barr Virus Infection: Phytochemical, Clinical, and Preclinical Studies, and the Prevalence and Impact on Patients with Hematological Diseases

Cytomegalovirus is a common virus that causes congenital illnesses. The lytic infection of the Epstein-Barr virus (EBV) has a substantial role in carcinogenesis. As a result, novel techniques for treating EBV-associated cancers have targeted the EBV lytic cycle. We emphasize recent discoveries addressing the function of the EBV lytic cycle in carcinogenesis in this analysis, which focuses on viral lytic proteins. There are also two EBV lytic cycle-targeted treatment options for EBV-induced cancers described. One method uses natural chemicals with anti-EBV characteristics to block the EBV lytic cycle, while another uses nucleoside analogs to trigger EBV lytic replication purposefully. EBV lytic-based techniques have shown the ability to deal with and/or preclusion of EBV-linked malignancies in recent years. The majority of currently licensed anti-viral medications possess side effects somehow, which necessitates the creation of anti-virals based on natural phytochemicals. Anti-viral development is transitioning to plant-derived drugs throughout the world since they are less harmful and have a lower potential of developing resistance. Phytochemicals have a long history of treating various ailments by suppressing viral replication and transcription – most block viruses during their entrance into the host cell or reproduction. Plant antioxidant phytochemicals such as flavonoids, terpenoids, lignins, alkaloids, and coumarins help to restrict viral genome replication. Plant-derived compounds treat viruses, including herpes virus, Epstein-Barr virus, and cytomegalovirus.